Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 441 participants.

Also called NCT01994889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 441 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01994889
  • EudraCT 2012-002465-35
Other papers using this trial's data
  • Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial JAMA cardiology, 2023-03-01 DOI, PubMed 36723935, PMC9996391 Not in the PMC Open Access subset.
  • Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]) The American journal of cardiology, 2021-06-01 DOI, PubMed 33667442
  • Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial JAMA cardiology, 2024-01-01 DOI, PubMed 37966817, PMC10652219 In the PMC Open Access subset under CC BY-NC-ND.
  • Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) The American journal of cardiology, 2021-02-15 DOI, PubMed 33220323
  • Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy The New England journal of medicine, 2018-09-13 DOI, PubMed 30145929

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Japan, Netherlands, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01994889. Randomized; quadruple masking; primary purpose treatment. Start 2013-12-09 (actual); primary completion 2018-02-07 (actual). Results posted on 2019-04-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
Acronym
ATTR-ACT
Condition
Transthyretin (TTR) Amyloid Cardiomyopathy
Intervention (Drug)
Tafamidis
Intervention (Drug)
Tafamidis
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01994889
Content hash
383789cd1d6556983c73bbf35b3e4c214f05ace447f73ff31f7021f8b6778d30